Clinical Trials Logo

Smell Disorders clinical trials

View clinical trials related to Smell Disorders.

Filter by:
  • None
  • Page 1

NCT ID: NCT05364125 Recruiting - Anosmia Clinical Trials

Olfactory Training on Smell Dysfunction Patients in HK

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

- Causes of olfactory dysfunction can be classified into conductive and sensorineural causes. - Conductive causes are mainly due to structural nasal problem, which can be treated by nasal surgery - Sensorineural causes included post-infection, post-head injury, post Head and Neck irradiation and other central nervous system diseases. - Olfactory Training is well established treatment for sensorineural olfactory dysfunction in foreign countries. - Olfactory Training by neurological chemosensory stimulation using aromatic substances delivered via electronic portable aromatic rehabilitation (EPAR) diffuser was proved to be effective treatment in COVID-19 related olfactory dysfunction in recent Hong Kong study. - However, there is a lack of local study on the effect of Olfactory Training in other non-COVID-19 sensorineural causes of olfactory dysfunction in Hong Kong population.

NCT ID: NCT05177445 Not yet recruiting - Smell Disorders Clinical Trials

Efficacy and Safety of Phototherapy in the Treatment of Loss of Smell Post Acute Infection of Coronavirus 19

Start date: April 2022
Phase: N/A
Study type: Interventional

The aim of this study is to assess whether the use of a therapy combining olfactory training, corticoids, and phototherapy improves the PROMS compared to the use of olfactory training and corticosteroids only. To accomplish this goal the study will consist of 40 participants. The participants must present olfactory dysfunction for at least 4 weeks after a coronavirus-19 infection. Furthermore, to be eligible each participant will need a polymerase chain reaction test with positive results for coronavirus-19.

NCT ID: NCT04661800 Not yet recruiting - Amyloidosis Clinical Trials

Study of Olfactory Disorders in Patients With Cardiac Amyloidosis

AMYLODOR
Start date: March 19, 2021
Phase: N/A
Study type: Interventional

Amyloidosis is a disease caused by the continuous accumulation of fibrillary proteins in the extracellular matrix causing the architecture of different organs to be disrupted. The prevalence of the disease increases with age. The two most common forms are light chain amyloidosis (AL) and transthyretin (TTR). TTR amyloidosis may be hereditary (m-TTR, or mutated) or age-related (WT-TTR, or wild). The latter is also called senile amyloidosis. In all these forms, cardiac impairment is common and leads the patient to consult/or be referred to a cardiological center unfortunately often too late when the prognosis is directly related to the severity of the heart attack. The description/discovery of clinical signs prior to heart disease is important to improve the detection and diagnosis of early forms of cardiac amyloidosis (CA). For example, an infiltration of the carpal tunnel synovial by amyloid deposits is observed in some patients, 5 years before the onset of signs of heart failure and is the only warning sign of the disease known to date. We also showed in a previous study that patients had more severe and earlier impairment of hearing function than expected by age and gender. Objective The main objective is to define the prevalence and severity of smell and taste disorders in a population of patients with cardiac amyloidosis (3 types of mutated or wild AL amyloidosis and TTR). The main endpoint is to determine the number of patients with impaired smell and taste's functions in a population of patients diagnosed with cardiac amyloidosis (3 types of mutated (hereditary) or senile wild amyloidosis (3 types of AL amyloidosis and TTR). Method Successive monocentric cross-sectional study on the screening of smell and taste disorders carried out as part of a cardiology hospitalization programmed for the cardiology follow-up of his pathology in a population of patients diagnosed with AC.